PL2813491T3 - Pochodna cykloalkanu - Google Patents

Pochodna cykloalkanu

Info

Publication number
PL2813491T3
PL2813491T3 PL13746373T PL13746373T PL2813491T3 PL 2813491 T3 PL2813491 T3 PL 2813491T3 PL 13746373 T PL13746373 T PL 13746373T PL 13746373 T PL13746373 T PL 13746373T PL 2813491 T3 PL2813491 T3 PL 2813491T3
Authority
PL
Poland
Prior art keywords
cycloalkane derivative
cycloalkane
derivative
Prior art date
Application number
PL13746373T
Other languages
English (en)
Polish (pl)
Inventor
Tsuyoshi Shinozuka
Hiroyuki Kobayashi
Sayaka Suzuki
Kyosuke Tanaka
Hiroko Kimoto
Yuki Domon
Original Assignee
Daiichi Sankyo Company, Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Company, Limited filed Critical Daiichi Sankyo Company, Limited
Publication of PL2813491T3 publication Critical patent/PL2813491T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/06Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D285/00Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01Five-membered rings
    • C07D285/02Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/081,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433Thidiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL13746373T 2012-02-09 2013-02-08 Pochodna cykloalkanu PL2813491T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2012025754 2012-02-09
JP2012259122 2012-11-27
EP13746373.3A EP2813491B1 (en) 2012-02-09 2013-02-08 Cycloalkane derivative

Publications (1)

Publication Number Publication Date
PL2813491T3 true PL2813491T3 (pl) 2017-08-31

Family

ID=48947609

Family Applications (1)

Application Number Title Priority Date Filing Date
PL13746373T PL2813491T3 (pl) 2012-02-09 2013-02-08 Pochodna cykloalkanu

Country Status (30)

Country Link
US (3) US8889741B2 (enExample)
EP (2) EP2813491B1 (enExample)
JP (2) JP5997710B2 (enExample)
KR (1) KR20140127238A (enExample)
CN (1) CN104185629B (enExample)
AU (1) AU2013218592B2 (enExample)
BR (1) BR112014019478A2 (enExample)
CA (1) CA2864222C (enExample)
CO (1) CO7151511A2 (enExample)
CY (1) CY1118572T1 (enExample)
DK (1) DK2813491T3 (enExample)
ES (2) ES2613078T3 (enExample)
HR (1) HRP20161713T1 (enExample)
HU (2) HUE031450T2 (enExample)
IL (1) IL234014A (enExample)
IN (1) IN2014MN01577A (enExample)
LT (1) LT2813491T (enExample)
MX (1) MX349354B (enExample)
NZ (1) NZ628096A (enExample)
PH (2) PH12014501804A1 (enExample)
PL (1) PL2813491T3 (enExample)
PT (1) PT2813491T (enExample)
RS (1) RS55671B1 (enExample)
RU (1) RU2635354C2 (enExample)
SG (1) SG11201404707VA (enExample)
SI (1) SI2813491T1 (enExample)
SM (2) SMT201700053T1 (enExample)
TW (1) TWI612042B (enExample)
WO (1) WO2013118854A1 (enExample)
ZA (1) ZA201405801B (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104024251B (zh) * 2011-10-31 2017-08-11 克赛农制药股份有限公司 苯磺酰胺化合物及其作为治疗剂的用途
CN104093716B (zh) 2011-10-31 2017-06-23 克赛农制药股份有限公司 联芳醚磺酰胺化合物及其作为治疗剂的用途
US8889741B2 (en) * 2012-02-09 2014-11-18 Daiichi Sankyo Company, Limited Cycloalkane derivatives
AR091112A1 (es) 2012-05-22 2015-01-14 Genentech Inc Benzamidas n-sustituidas como inhibidores de los canales de sodio nav1.7
BR112015000187A2 (pt) 2012-07-06 2017-06-27 Genentech Inc benzamidas substituídas com n e métodos de uso das mesmas
US9597330B2 (en) 2013-03-14 2017-03-21 Daiichi Sankyo Company, Limited Drugs for treating respiratory diseases
CN105263490B (zh) 2013-03-14 2018-05-22 基因泰克公司 取代的三唑并吡啶及其使用方法
MX2015010775A (es) 2013-03-15 2016-04-25 Genentech Inc Benzoxazoles sustituidos y metodos para usarlos.
EA201691085A1 (ru) 2013-11-27 2017-02-28 Дженентек, Инк. Замещенные бензамиды и способы их применения
WO2016007534A1 (en) 2014-07-07 2016-01-14 Genentech, Inc. Therapeutic compounds and methods of use thereof
JP2018520107A (ja) 2015-05-22 2018-07-26 ジェネンテック, インコーポレイテッド 置換ベンズアミド及びその使用方法
JP2018526371A (ja) 2015-08-27 2018-09-13 ジェネンテック, インコーポレイテッド 治療化合物及びその使用方法
SG10202007787RA (en) 2015-09-28 2020-09-29 Genentech Inc Therapeutic compounds and methods of use thereof
CN108349894A (zh) 2015-11-06 2018-07-31 第三共株式会社 除去二甲氧基苄基的方法
US10899732B2 (en) 2015-11-25 2021-01-26 Genentech, Inc. Substituted benzamides useful as sodium channel blockers
EP3436432B1 (en) 2016-03-30 2021-01-27 Genentech, Inc. Substituted benzamides and methods of use thereof
TN2018000385A1 (en) * 2016-05-20 2020-06-15 Xenon Pharmaceuticals Inc Benzenesulfonamide compounds and their use as therapeutic agents
CN110072855A (zh) 2016-10-17 2019-07-30 基因泰克公司 治疗性化合物及其使用方法
EP3532462B1 (en) * 2016-10-27 2021-10-13 Bristol-Myers Squibb Company Acyl sulfonamide nav1.7 inhibitors
SG10201912376VA (en) 2016-12-09 2020-02-27 Xenon Pharmaceuticals Inc Benzenesulfonamide compounds and their use as therapeutic agents
EP3601273B1 (en) 2017-03-24 2021-12-01 Genentech, Inc. 4-piperidin-n-(pyrimidin-4-yl)chroman-7-sulfonamide derivatives as sodium channel inhibitors
EP3684772B1 (en) 2017-09-20 2023-12-06 ABM Therapeutics Corporation Cyclic iminopyrimidine derivatives as kinase inhibitors
US11028075B2 (en) 2018-02-26 2021-06-08 Genentech, Inc. Therapeutic compounds and methods of use thereof
CN111936494A (zh) 2018-03-30 2020-11-13 豪夫迈·罗氏有限公司 作为钠通道抑制剂的取代的氢-吡啶并-吖嗪
TW202003490A (zh) 2018-05-22 2020-01-16 瑞士商赫孚孟拉羅股份公司 治療性化合物及其使用方法
BR112020024729A2 (pt) 2018-06-13 2021-03-23 Xenon Pharmaceuticals, Inc. compostos de benzenossulfonamida e seu uso como agentes terapêuticos
IL279810B2 (en) 2018-08-31 2025-03-01 Xenon Pharmaceuticals Inc Heteroaryl-modified sulfonamide compounds and their use as medicinal agents
JP7383012B2 (ja) 2018-08-31 2023-11-17 ゼノン・ファーマシューティカルズ・インコーポレイテッド ヘテロアリール置換スルホンアミド化合物、およびナトリウムチャネル阻害剤としてのその使用
CN113164461A (zh) * 2018-12-26 2021-07-23 拉夸里亚创药株式会社 作为Nav1.7及Nav1.8阻断剂的杂环衍生物
US20240241265A1 (en) * 2023-01-18 2024-07-18 Qualcomm Incorporated Virtual positioning signal measurements

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6222048B1 (en) 1995-12-18 2001-04-24 Merck Frosst Canada & Co. Diaryl-2-(5H)-furanones as Cox-2 inhibitors
WO2006038594A1 (ja) 2004-10-04 2006-04-13 Ono Pharmaceutical Co., Ltd. N型カルシウムチャネル阻害薬
ZA200710332B (en) * 2005-05-16 2009-03-25 Vertex Pharma Bicyclic derivatives as modulators of ion channels
US8124610B2 (en) 2007-07-13 2012-02-28 Icagen Inc. Sodium channel inhibitors
WO2010035166A1 (en) 2008-09-23 2010-04-01 Pfizer Limited Benzamide derivatives
CU24099B1 (es) * 2009-01-12 2015-06-30 Pfizer Ltd Derivados de sulfonamida para el tratamiento del dolor
EP2590951B1 (en) * 2010-07-09 2015-01-07 Pfizer Limited Benzenesulfonamides useful as sodium channel inhibitors
JP5872552B2 (ja) * 2010-07-09 2016-03-01 ファイザー・リミテッドPfizer Limited 化学化合物
EP2590957B1 (en) 2010-07-09 2014-11-12 Pfizer Limited N-sulfonylbenzamides as inhibitors of voltage-gated sodium channels
CN104024251B (zh) * 2011-10-31 2017-08-11 克赛农制药股份有限公司 苯磺酰胺化合物及其作为治疗剂的用途
US8889741B2 (en) * 2012-02-09 2014-11-18 Daiichi Sankyo Company, Limited Cycloalkane derivatives

Also Published As

Publication number Publication date
SMT201700053B (it) 2017-03-08
BR112014019478A2 (pt) 2019-05-28
DK2813491T3 (en) 2017-02-13
HUE037048T2 (hu) 2018-08-28
IN2014MN01577A (enExample) 2015-05-08
MX2014009637A (es) 2015-06-23
AU2013218592B2 (en) 2016-12-22
WO2013118854A1 (ja) 2013-08-15
EP2813491A4 (en) 2015-08-12
US9493448B2 (en) 2016-11-15
US20170001984A1 (en) 2017-01-05
RU2635354C2 (ru) 2017-11-13
TWI612042B (zh) 2018-01-21
PH12015502675A1 (en) 2017-04-24
EP3144300B1 (en) 2017-12-20
IL234014A (en) 2017-09-28
HK1203503A1 (en) 2015-10-30
JPWO2013118854A1 (ja) 2015-05-11
TW201339152A (zh) 2013-10-01
MX349354B (es) 2017-07-24
JP6154052B2 (ja) 2017-06-28
EP2813491A1 (en) 2014-12-17
IL234014A0 (en) 2014-09-30
SI2813491T1 (sl) 2017-02-28
ES2613078T3 (es) 2017-05-22
RS55671B1 (sr) 2017-06-30
JP2017008093A (ja) 2017-01-12
PT2813491T (pt) 2017-02-10
CY1118572T1 (el) 2017-07-12
PH12014501804B1 (en) 2014-11-17
CA2864222A1 (en) 2013-08-15
US8889741B2 (en) 2014-11-18
PH12014501804A1 (en) 2014-11-17
ES2659434T3 (es) 2018-03-15
CN104185629B (zh) 2017-10-13
AU2013218592A1 (en) 2014-09-18
CA2864222C (en) 2016-10-25
HRP20161713T1 (hr) 2017-02-10
HUE031450T2 (en) 2017-07-28
KR20140127238A (ko) 2014-11-03
EP2813491B1 (en) 2016-11-02
RU2014136463A (ru) 2016-03-27
SG11201404707VA (en) 2014-10-30
CN104185629A (zh) 2014-12-03
CO7151511A2 (es) 2014-12-29
LT2813491T (lt) 2017-02-10
US9845313B2 (en) 2017-12-19
ZA201405801B (en) 2015-12-23
SMT201700053T1 (it) 2017-03-08
NZ628096A (en) 2016-06-24
US20150018551A1 (en) 2015-01-15
US20140045862A1 (en) 2014-02-13
EP3144300A1 (en) 2017-03-22
JP5997710B2 (ja) 2016-09-28

Similar Documents

Publication Publication Date Title
ZA201405801B (en) Cycloalkane derivative
ZA201407694B (en) Substituted pyrrolidine-2-carboxamides
DK3327112T3 (en) Agse-deficient stamme
DK2830816T3 (en) Hidtil ukendt coatingkoncept
IL238221A0 (en) self-injector
SG11201404344XA (en) Substituted pyrrolidine-2-carboxamides
EP2935220A4 (en) PERI-carbinol
GB201220843D0 (en) Compound
EP2874517A4 (en) SEAT LIFTING ARRANGEMENT
SG11201406871UA (en) Benzamide derivative
IL236295A (en) The history of indanesulfamide
EP2905847A4 (en) TOGETHER
EP2934541A4 (en) NORIBOGAINE SUBSTITUTE
EP2920142A4 (en) MÉTHANOFULLERRÈNES
ZA201405108B (en) Substituted phenylazole derivative
PT2873660T (pt) Derivado de indolecarboxamida
GB201216309D0 (en) Compound
GB201215675D0 (en) Compound
GB201216448D0 (en) Compound
GB201211594D0 (en) Language
GB201219170D0 (en) Pull
GB201220595D0 (en) Keysafe application
GB201222353D0 (en) Auto-injector
GB201213503D0 (en) Auto-injector
GB201213502D0 (en) Auto-injector